Research programme: eye disorder therapeutics - Abzyme Therapeutics
Latest Information Update: 08 Apr 2021
At a glance
- Originator Abzyme Therapeutics
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 23 Mar 2021 Eye disorder therapeutics is available for licensing as of 23 Mar 2021. http://abzymetx.com/pipeline/partnering/